MSN Laboratories Pvt Ltd

Medak, India

MSN Laboratories Pvt Ltd

Medak, India
SEARCH FILTERS
Time filter
Source Type

Ganesh Kumar Y.,Sree Dattha Institute of Pharmacy | Sreekanth J.,MSN Laboratories Pvt. Ltd | Satyavati D.,Sree Dattha Institute of Pharmacy
International Journal of Pharmacy and Pharmaceutical Sciences | Year: 2014

Methods: Bosentan SR Matrix tablets were prepared by Wet granulation method. The tablets were evaluated for Hardness, Thickness, Friability and Drug content and were subjected to a 12 hours in vitro drug release studies.Objective: Bosentan is an endothelin receptor antagonist (ERA) indicated for the treatment of Pulmonary arterial hypertension (PAH). The aim of the present study involves the development of sustained release matrix tablets of bosentan in order to release the drug in sustained and predictable manner.Results: The amount of Bosentan released from the tablet formulations at different time intervals was estimated using a UV Spectroscopy method. Among all the formulations are prepared by using different polymers like HPMC K 4 M, HPMC K15 M at different ratios.Conclusion: We Can Conclude that Among the Ten formulations, F-2 formulation containing drug to HPMC K 4 M in ratio 1:0.5 is optimized based on its ability to sustain drug release till 12 hours of dissolution study, The results of the study clearly demonstrated that HPMC matrix tablet formulation is an effective and promising drug delivery system for once daily administration of Bosentan. © 2014, International Journal of Pharmacy and Pharmaceutical Sciences. All right reserved.


Rakesh S.S.,MSN Laboratories Pvt Ltd | Basaveswara Rao M.V.,Krishna University | Sreekanth J.,MSN Laboratories Pvt Ltd
International Journal of Pharmaceutical Sciences Review and Research | Year: 2014

Modified release matrix tablets of Tapentadol hydrochloride were prepared with HPMC K100 M as retarding polymer by wet granulation method. The granules were evaluated for angle of repose, bulk density, tapped density, bulkiness, compressibility index and Hausners ratio. The tablets were subjected to weight variation, hardness, friability and drug content test. Invitro release studies revealed that Tapentadol formulation with high proportion of HPMC K100M was able to control the drug release for 12 hours. Fitting the invitro drug release data to kinetic analysis, optimized formulations followed the mechanism of diffusion. All the formulations were stored at 40ᵒC and 75%RH and subjected to stability studies up to 6 months. It showed that all the formulations are physically and chemically stable. © 2014, Global Research Online. All rights reserved.


Rakesh S.S.,MSN Laboratories Pvt Ltd | Basaveswara Rao M.V.,Krishna University | Sreekanth J.,MSN Laboratories Pvt Ltd
International Journal of Pharmaceutical Sciences Review and Research | Year: 2015

The objective of the present study was to develop and characterize extended release tablets of Pramipexole dihydrochloride monohydrate to be taken once daily. The combination of different polymers like hydroxypropyl methyl cellulose (HPMC K 100M) and Eudragit L 100 in varying concentrations were studied to get the desired extended release profile over a period of 24 h. The granules were evaluated for angle of repose, bulk density, compressibility index, and drug content and found to be satisfactory. Hydroxypropylmethylcellulose (HPMC K100M) at 50% level in combination with methacrylic acid copolymer (Eudragit L100) at 2.0% level producedextended release Pramipexole dihydrochloride monohydrate matrix tablets. The drug release of optimized formulation (F7) was extended up to 24 h in vitro study. The drug release pattern from the optimized matrix formulation (F7) was diffusion controlled. The innovator product Mirapex (0.375 mg) drug release profiles are shown to be followed first order release kinetics. The results suggested that combination of hydrophilic and hydrophobic polymers used in the preparation of extended release Pramipexole dihydrochloride monohydrate tablets, is a suitable method and it can perform therapeutically better. © 2014, Global Research Online. All rights reserved.


Ganesh Kumar Y.,Jawaharlal Nehru Technological University | Sreekanth J.,MSN Laboratories Pvt. Ltd | Satyavati D.,Brilliant Group of Institutions
International Journal of Pharmaceutical Sciences Review and Research | Year: 2015

The objective of the present study was to develop Bosentan monohydrate matrix tablets, sustained release dosage form, for the treatment of Pulmonary Arterial Hypertension Disease. Drug Excipient Compatibility study was performed through FTIR and DSC revealed that there no interaction between drug and polymers. Matrix tablets were prepared by wet granulation method using different concentration of Compritol 888 ATO, Poloxamer-407, and Poloxamer-188. Prepared formulations were subjected to Precompression parameters like angle of repose, bulk and tapped density, Hausner’s ratio and car’s index and post-compression parameters like hardness, friability, thickness, % drug content, and weight variation. All the formulations resulted in acceptable Pharmacopoeia limits. Tablets were subjected to In-Vitro drug release in 0.1 N HCl (pH 1.2) for first 2 hours followed by phosphate buffer (pH 6.8) for remaining 10 hours. The optimized formulation (F6) on the basis of acceptable tablet properties and In Vitro drug release. The resulting formulation produced robust tablets with optimum hardness, consistent weight uniformity and friability. A decrease in release kinetics of the drug was observed on increasing polymer ratio. Among all these formulations F-6 is optimized Based on Cumulative % Drug Release was found to be 97.5 ± 0.91 % in 12 hrs. In This formulation containing 62.5 mg of Bosentan Pure drug, 93.75mg of Poloxamer, PVP K-30, 6mg of Talc, 6mg of Mg.Stearate, and 131.75mg of MCC. As the result of this study it may conclude that the formulation meet the needed theoretical drug release profile and has the sustain action i.e., retarding the drug release so the release is for a long time and thus more Bioavailability. © 2015, Global Research Online. All rights reserved.


Kumar Y.G.,Jawaharlal Nehru University | Kumar Y.G.,Brilliant Group of Institutions Integrated Campus | Sreekanth J.,MSN Laboratories Pvt. Ltd | Satyavati D.,Brilliant Group of Institutions Integrated Campus
Asian Journal of Pharmaceutics | Year: 2015

Aim: The present research work was to design and develop the sustained release matrix tablets of vildagliptin. It is having a short biological half-life (1.5 h) so it is considered as a suitable drug for the formulation of sustained release tablets to prolong its therapeutic action. Vildagliptin is an oral antihyperglycemic agent of the new dipeptidyl peptidase-4 inhibitor class of drug. Materials and Methods: Matrix tablets were prepared by wet granulation technique, using synthetic and natural polymers at different ratios. Granules were prepared and evaluated for bulk density, tapped density, Hausner's ratio, compressibility index. Statistical Analysis Used: The Fourier-transform infrared spectra of the vildagliptin and different polymers alone and in a combination show the compatibility of the drug with excipients. Results: The physicochemical properties of tablets were found within the limits. The prepared tablets were evaluated for weight variation, thickness, hardness, % friability, % drug contents, and in vitro release. In vitro dissolution studies (USP dissolution rate test apparatus II, 50 rpm, 37°C ± 0.5°C) was carried out for the first 2 h in 0.1 N HCl (1.2 pH) and followed 6.8 phosphate buffer for 10 h as a dissolution medium. Conclusion: The optimized formulation F-8 was shown maximum drug release 97.56 ± 0.72% in 12 h of dissolution. The release kinetic data of formulation F-8 shown zero order (R2 = 9902).


PubMed | MSN Laboratories Pvt Ltd and Sri Krishnadevaraya University
Type: Journal Article | Journal: Journal of chromatographic science | Year: 2015

A novel, rapid, specific and stability-indicating reverse-phase high-performance liquid chromatography method was developed for the quantitative determination of related compounds, obtained from two different synthetic routes and degradation products of Azilsartan kamedoxomil (AZL). The method was developed by using a YMC-Pack pro C18 (150 4.6 mm, 3 m) column with a mobile phase containing a gradient mobile phase combination. The eluted compounds were measured at wavelength 220 nm. The developed method run time was 25 min, within which AZL and its eight impurities were well separated with minimum 3.0 resolution. The drug substance was subjected to stress conditions of hydrolysis (acid, base and water), oxidation, photolysis, sunlight, 75% relative humidity and thermal degradation as per International Conference on Harmonization (ICH) prescribed stress conditions to ascertain the stability-indicating power of the method. Significant degradation was observed during acid, base, peroxide, water hydrolysis and 75% relative humidity studies. The mass balance of AZL was close to 100% in all the stress condition. The developed method was validated as per the ICH guidelines with respect to specificity, linearity, limit of detection, limit of quantification, accuracy, precision and robustness.


Sahadev Reddy M.,MSN Laboratories Pvt. Ltd | Sahadev Reddy M.,Rayalaseema University | Reddy M.S.N.,MSN Laboratories Pvt. Ltd | Rajan S.T.,MSN Laboratories Pvt. Ltd | And 2 more authors.
Der Pharma Chemica | Year: 2016

An improved and efficient synthetic process developed for an oxidation of primary alcohols to related aldehydes with commercially cheaper trichloroisocyanuric acid in presence of catalyst TEMPO (2, 2, 6, 6-tetra methyl-1-piperidinyloxy Free radical). This synthetic approach efficiently provides highly pure aldehydes without formation of the acid impurity. In the present process overall yields are around 90-95%.


Sahadev Reddy M.,MSN Laboratories Pvt. Ltd | Sahadev Reddy M.,Rayalaseema University | Reddy M.S.N.,MSN Laboratories Pvt. Ltd | Rajan S.T.,MSN Laboratories Pvt. Ltd | And 2 more authors.
Der Pharma Chemica | Year: 2016

In the synthesis of Esmolol hydrochloride four prominent process impurities were formed during synthesis. These impurities were detected in gradient HPLC method. These impurities are synthesized in different synthesis methods and characterized as 3-(4-(2-hydroxy-3-(isopropyl amino) propoxy) phenyl)propanoic acid (Esmolol free acid), Methyl 3-4-[3-(ethyl amino)-2-hydroxy propoxy]phenyl propionate (Esmolol isopropyl amide analog), 3-(4-(2-hydroxy-3(isopropylamino)propoxy)phenyl)-N-isopropylpropanamide (N-Ethyl Esmolol), Methyl 3-(4-(2-hydroxy-3-(3-(4-(2-hydroxy-3-(isopropylamino) propoxy) phenyl)-N-isopropyl propanamido) propoxy)phenyl)propanoate (Esmolol dimer) by 1H NMR, IR and Mass spectral data. Synthesis and Structural elucidation by spectral data is discussed.


Sahadeva Reddy M.,MSN Laboratories Pvt. Ltd | Sahadeva Reddy M.,Rayalaseema University | Reddy M.S.N.,MSN Laboratories Pvt. Ltd | Rajan S.T.,MSN Laboratories Pvt. Ltd | And 2 more authors.
Der Pharma Chemica | Year: 2016

A novel and efficient synthetic process developed for Pitavastatin calcium by preparation of key intermediate 2 with high yield and quality by condensing 2-cyclopropyl-4-(4-fluorophenyl)-3-((1-methyl-1H-benzo[d]imidazol-2- ylsulfonyl)methyl) quinoline 13 with (3R,5S)-tert-butyl 3,5-dimethoxy-6-oxohexanoate 10. This synthetic approach efficiently provides highly pure Pitavastatin calcium with high yields.


Kotla N.R.,MSN Laboratories Pvt. Ltd | Kotla N.R.,Rayalaseema University | Nagaraju C.V.S.,MSN Laboratories Pvt. Ltd | Rajan S.T.,MSN Laboratories Pvt. Ltd | And 6 more authors.
Der Pharma Chemica | Year: 2014

A reverse phase liquid chromatographic (RP-LC) method was developed for the quantification of the related impurities of Fingolimod hydrochloride drug substance. The method was optimized using buffer (prepared by dissolving 2.72gr KH2PO4 and 2.0gm 1-Octane sulphonoic acid sodium salt anhydrous taken in 1000mL milli-Qwater and then pH was adjusted to ~ 3.0 with dilute orthophospharic acid solution) as mobilephase-A, and Acetonitrile: water in the ratio of 90:10 v/v as mobile phase-B. The flow rate was set at 1.2 mL min-1, wavelength at 220nm respectively and the column temperature was maintained at 45 °C. The capability of stability indicating method developed was demonstrated by studying the degradation products generated during the forced degradation studies under the following conditions i) water hydrolysis, ii) at 75% relative humidity, iii) oxidative, iv) thermal v) photolytic, vi) acid, vii) base, and viii) photolytic degradation. The developed method can be used for the determination of synthetic and degradation impurities in the regular quality control analysis for the drug substance.

Loading MSN Laboratories Pvt Ltd collaborators
Loading MSN Laboratories Pvt Ltd collaborators